Tony Michael Argenbright
Examiner (ID: 16324)
Most Active Art Unit | 3402 |
Art Unit(s) | 3402, 3747 |
Total Applications | 2731 |
Issued Applications | 2589 |
Pending Applications | 40 |
Abandoned Applications | 102 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17314461
[patent_doc_number] => 20210403509
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => S-LAYER VACCINE FUSION PROTEINS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/353965
[patent_app_country] => US
[patent_app_date] => 2021-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10247
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17353965
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/353965 | S-LAYER VACCINE FUSION PROTEINS AND METHODS OF USE | Jun 21, 2021 | Pending |
Array
(
[id] => 17503250
[patent_doc_number] => 20220096352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => HUMAN PLACENTAL COLLAGEN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/302831
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31588
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17302831
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/302831 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | May 12, 2021 | Abandoned |
Array
(
[id] => 17960053
[patent_doc_number] => 20220340633
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES
[patent_app_type] => utility
[patent_app_number] => 17/316153
[patent_app_country] => US
[patent_app_date] => 2021-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316153
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/316153 | SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES | May 9, 2021 | Pending |
Array
(
[id] => 18101235
[patent_doc_number] => 11541104
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week
[patent_app_type] => utility
[patent_app_number] => 17/315020
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 27936
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315020
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/315020 | Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week | May 6, 2021 | Issued |
Array
(
[id] => 17023535
[patent_doc_number] => 20210247406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/244214
[patent_app_country] => US
[patent_app_date] => 2021-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7319
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244214
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/244214 | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases | Apr 28, 2021 | Issued |
Array
(
[id] => 17183857
[patent_doc_number] => 20210330742
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING RUNX3 PROTEIN AND CDK4 INHIBITOR OR mTOR INHIBITOR COTREATMENT FOR PREVENTION OR TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/239433
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6293
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239433
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/239433 | PHARMACEUTICAL COMPOSITION COMPRISING RUNX3 PROTEIN AND CDK4 INHIBITOR OR mTOR INHIBITOR COTREATMENT FOR PREVENTION OR TREATMENT OF CANCER | Apr 22, 2021 | Pending |
Array
(
[id] => 17355421
[patent_doc_number] => 20220016217
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => COMBINATION OF AN INSULIN AND A GLP-1-AGONIST
[patent_app_type] => utility
[patent_app_number] => 17/237632
[patent_app_country] => US
[patent_app_date] => 2021-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13562
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17237632
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/237632 | COMBINATION OF AN INSULIN AND A GLP-1-AGONIST | Apr 21, 2021 | Abandoned |
Array
(
[id] => 17170339
[patent_doc_number] => 20210324009
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/220177
[patent_app_country] => US
[patent_app_date] => 2021-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11512
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220177
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/220177 | ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONS | Mar 31, 2021 | Pending |
Array
(
[id] => 17110135
[patent_doc_number] => 20210290732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => GLP-1R and GCGR Agonists, Formulations, and Methods of Use
[patent_app_type] => utility
[patent_app_number] => 17/180827
[patent_app_country] => US
[patent_app_date] => 2021-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47813
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180827
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180827 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | Feb 20, 2021 | Pending |
Array
(
[id] => 17034986
[patent_doc_number] => 20210251944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/177665
[patent_app_country] => US
[patent_app_date] => 2021-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55351
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17177665
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/177665 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | Feb 16, 2021 | Pending |
Array
(
[id] => 19624155
[patent_doc_number] => 12162959
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-10
[patent_title] => Cyclic peptide for treating cancer
[patent_app_type] => utility
[patent_app_number] => 17/176983
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 9
[patent_no_of_words] => 4830
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 215
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176983
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176983 | Cyclic peptide for treating cancer | Feb 15, 2021 | Issued |
Array
(
[id] => 17140214
[patent_doc_number] => 20210308225
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => Long-Acting Formulations of Insulin
[patent_app_type] => utility
[patent_app_number] => 17/176442
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176442
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176442 | Long-Acting Formulations of Insulin | Feb 15, 2021 | Pending |
Array
(
[id] => 16977629
[patent_doc_number] => 20210221866
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS
[patent_app_type] => utility
[patent_app_number] => 17/169833
[patent_app_country] => US
[patent_app_date] => 2021-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17169833
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/169833 | PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS | Feb 7, 2021 | Abandoned |
Array
(
[id] => 16855173
[patent_doc_number] => 20210155918
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => RECOMBINANT PROTHROMBIN ANALOGUES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/157130
[patent_app_country] => US
[patent_app_date] => 2021-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14175
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157130
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/157130 | Recombinant prothrombin analogues and uses thereof | Jan 24, 2021 | Issued |
Array
(
[id] => 17096894
[patent_doc_number] => 20210284685
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => METHODS FOR REMOVING A CONTAMINANT USING INDIGENOUS PROTEIN DISPLACEMENT ION EXCHANGE MEMBRANE CHROMATOGRAPHY
[patent_app_type] => utility
[patent_app_number] => 17/153826
[patent_app_country] => US
[patent_app_date] => 2021-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15225
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153826
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/153826 | METHODS FOR REMOVING A CONTAMINANT USING INDIGENOUS PROTEIN DISPLACEMENT ION EXCHANGE MEMBRANE CHROMATOGRAPHY | Jan 19, 2021 | Pending |
Array
(
[id] => 16839565
[patent_doc_number] => 20210147577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => Mutated Immunoglobulin-Binding Polypeptides
[patent_app_type] => utility
[patent_app_number] => 17/149830
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149830
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/149830 | Mutated Immunoglobulin-Binding Polypeptides | Jan 14, 2021 | Pending |
Array
(
[id] => 16807846
[patent_doc_number] => 20210130399
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => PROTEIN PURIFICATION
[patent_app_type] => utility
[patent_app_number] => 17/145233
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13636
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17145233
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/145233 | PROTEIN PURIFICATION | Jan 7, 2021 | Abandoned |
Array
(
[id] => 16885376
[patent_doc_number] => 20210171571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => PROTEIN PURIFICATION
[patent_app_type] => utility
[patent_app_number] => 17/145235
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13638
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17145235
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/145235 | PROTEIN PURIFICATION | Jan 7, 2021 | Abandoned |
Array
(
[id] => 16807845
[patent_doc_number] => 20210130398
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => PROTEIN PURIFICATION
[patent_app_type] => utility
[patent_app_number] => 17/145231
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13602
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17145231
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/145231 | PROTEIN PURIFICATION | Jan 7, 2021 | Abandoned |
Array
(
[id] => 16948144
[patent_doc_number] => 20210206835
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => Self-Assembling Collagen-Like Polypeptides for Applications and Uses Related Thereto
[patent_app_type] => utility
[patent_app_number] => 17/140449
[patent_app_country] => US
[patent_app_date] => 2021-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7390
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 208
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17140449
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/140449 | Self-Assembling Collagen-Like Polypeptides for Applications and Uses Related Thereto | Jan 3, 2021 | Pending |